Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484041 · ClinicalTrials.gov registry record · Phase 1
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
A Phase 1 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01484041 is a Phase 1 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 12 participants.
The verdict
NCT01484041, a Phase 1 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is for women with confirmed hormone receptor positive HER-2 negative advanced breast cancer with evidence of disease resistance to an aromatase inhibitor. The purpose of this study is to determine how well these medications work together and/or if they have any side effects in patients with hormone-receptor positive metastatic breast cancer who have demonstrated progression of disease after first line hormonal therapy. This research is being done to determine if taking an already approved medicine (aromatase inhibitor) in combination with a new medication (dovitinib) results in better outcomes for patients with this disease. Both dovitinib and an aromatase inhibitor are pills that will be taken at home.
Interventions
- DRUG Dovitinib
- DRUG Aromatase Inhibitors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-04 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01484041
The ClinicalTrials.gov registry entry for NCT01484041 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dovitinib is the first listed.
NCT01484041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01484041 about?
NCT01484041 is a clinical study titled "Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer". This study is for women with confirmed hormone receptor positive HER-2 negative advanced breast cancer with evidence of disease resistance to an aromatase inhibitor. The purpose of this study is to determine how well these medications work together and/or if they have any side effects in patients w...
What is the current status of trial NCT01484041?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-04. Estimated completion is 2017-12.
What interventions are being tested in trial NCT01484041?
The interventions under investigation include: Dovitinib (DRUG), Aromatase Inhibitors (DRUG).
Who is sponsoring clinical trial NCT01484041?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.